Michael P. Hill
About
Michael P. Hill is a scholar working on Cellular and Molecular Neuroscience, Neurology and Molecular Biology.
According to data from OpenAlex, Michael P. Hill has authored 40 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Cellular and Molecular Neuroscience, 24 papers in Neurology and 8 papers in Molecular Biology. Recurrent topics in Michael P. Hill's work include Neuroscience and Neuropharmacology Research (24 papers), Parkinson's Disease Mechanisms and Treatments (23 papers) and Neurological disorders and treatments (18 papers). Michael P. Hill is often cited by papers focused on Neuroscience and Neuropharmacology Research (24 papers), Parkinson's Disease Mechanisms and Treatments (23 papers) and Neurological disorders and treatments (18 papers). Michael P. Hill collaborates with scholars based in United Kingdom, France and Canada. Michael P. Hill's co-authors include Jonathan M. Brotchie, Alan R. Crossman, Susan H. Fox, Vincenzo Di Marzo, Erwan Bézard, Tiziana Bisogno, Katarzyna Sieradzan, Jeremy Dick, Paula Ravenscroft and Joanne E. Nash and has published in prestigious journals such as PLoS ONE, Neurology and The FASEB Journal.
In The Last Decade
Michael P. Hill
40 papers receiving 2.2k citations
Peers
Michael P. Hill
Anders Borgkvist Sweden
Junchao Tong Canada
Annalisa Pinna Italy
Krystyna Ossowska Poland
Jadwiga Wardas Poland
Christophe Melon France
O. Curet France
Joakim Tedroff Sweden
Patricia Tagliaferro Argentina
Maria Rosaria Domenici Italy
Citations per year, relative to Michael P. Hill Michael P. Hill (= 1×)
peers
Anders Borgkvist
Countries citing papers authored by Michael P. Hill
Since
Specialization
Citations
This map shows the geographic impact of Michael P. Hill's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael P. Hill with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael P. Hill more than expected).
Fields of papers citing papers by Michael P. Hill
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Michael P. Hill. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael P. Hill. The network helps show where Michael P. Hill may publish in the future.
Co-authorship network of co-authors of Michael P. Hill
This figure shows the co-authorship network connecting the top 25 collaborators of Michael P. Hill. A scholar is included among the top collaborators of Michael P. Hill based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael P. Hill. Michael P. Hill is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Schneider, Jay S., Nathaniel W. Snyder, Michael P. Hill, et al.. (2020). A novel dopamine D3R agonist SK609 with norepinephrine transporter inhibition promotes improvement in cognitive task performance in rodent and non-human primate models of Parkinson's disease. Experimental Neurology. 335. 113514–113514.
2.
Howson, Patrick A., Tom H. Johnston, Paula Ravenscroft, et al.. (2019). Beneficial Effects of Trehalose on Striatal Dopaminergic Deficits in Rodent and Primate Models of Synucleinopathy in Parkinson’s Disease. Journal of Pharmacology and Experimental Therapeutics. 369(3). 364–374.
3.
Brigham, Elizabeth, Tom H. Johnston, Jonathon Holt, et al.. (2018). Pharmacokinetic/Pharmacodynamic Correlation Analysis of Amantadine for Levodopa-Induced Dyskinesia. Journal of Pharmacology and Experimental Therapeutics. 367(2). 373–381.
4.
Jaunarajs, Karen L. Eskow, David G. Standaert, Tacey X. Viegas, et al.. (2013). Rotigotine polyoxazoline conjugate SER‐214 provides robust and sustained antiparkinsonian benefit. Movement Disorders. 28(12). 1675–1682.
5.
Kobylecki, Christopher, Michael P. Hill, Alan R. Crossman, & Paula Ravenscroft. (2011). Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease. Movement Disorders. 26(13). 2354–2363.
6.
Barraud, Quentin, Virginie Lambrecq, Claude Forni, et al.. (2009). Sleep disorders in Parkinson's disease: The contribution of the MPTP non-human primate model. Experimental Neurology. 219(2). 574–582.
7.
Scheller, D., Hermann Lübbert, Grégory Porras, et al.. (2008). Neuroprotective effects of rotigotine in the acute MPTP-lesioned mouse model of Parkinson's disease. Neuroscience Letters. 432(1). 30–34.
8.
Millan, Mark J., Per Svenningsson, Charles R. Ashby, et al.. (2007). S33138 [N-[4-[2-[(3 aS,9 bR)-8-Cyano-1,3 a,4,9 b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3 H)-yl)-ethyl]phenylacetamide], a Preferential Dopamine D3 versus D2 Receptor Antagonist and Potential Antipsychotic Agent. II. A Neurochemical, Electrophysiological and Behavioral Characterization in Vivo. Journal of Pharmacology and Experimental Therapeutics. 324(2). 600–611.
9.
Hill, Michael P., Paula Ravenscroft, Jonathan M. Brotchie, et al.. (2006). Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP‐lesioned marmosets: Mediation by D2, not D3, dopamine receptors. Movement Disorders. 21(12). 2090–2095.
10.
Scheller, D., Piu Chan, Qin Li, et al.. (2006). Rotigotine treatment partially protects from MPTP toxicity in a progressive macaque model of Parkinson's disease. Experimental Neurology. 203(2). 415–422.
11.
Hill, Michael P., Jonathan M. Brotchie, Alan R. Crossman, et al.. (2004). Levetiracetam Interferes With the l-Dopa Priming Process in MPTP-Lesioned Drug-Naive Marmosets. Clinical Neuropharmacology. 27(4). 171–177.
12.
Hill, Michael P., Paula Ravenscroft, Erwan Bézard, et al.. (2004). Levetiracetam Potentiates the Antidyskinetic Action of Amantadine in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-Lesioned Primate Model of Parkinson’s Disease. Journal of Pharmacology and Experimental Therapeutics. 310(1). 386–394.
13.
Millan, Mark J., Benjamin Di Cara, Michael P. Hill, et al.. (2004). S32504, a Novel Naphtoxazine Agonist at Dopamine D3/D2 Receptors: II. Actions in Rodent, Primate, and Cellular Models of Antiparkinsonian Activity in Comparison to Ropinirole. Journal of Pharmacology and Experimental Therapeutics. 309(3). 921–935.
14.
Hill, Michael P., Erwan Bézard, Alan R. Crossman, et al.. (2003). Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L ‐dopa and ropinirole in the MPTP‐lesioned marmoset. Movement Disorders. 18(11). 1301–1305.
15.
Savola, Juha‐Matti, Michael P. Hill, Mia Engström, et al.. (2003). Fipamezole (JP‐1730) is a potent α2 adrenergic receptor antagonist that reduces levodopa‐induced dyskinesia in the MPTP‐lesioned primate model of Parkinson's disease. Movement Disorders. 18(8). 872–883.
16.
Fox, Susan H., Brian Henry, Michael P. Hill, Alan R. Crossman, & Jonathan M. Brotchie. (2002). Stimulation of cannabinoid receptors reduces levodopa‐induced dyskinesia in the MPTP‐lesioned nonhuman primate model of Parkinson's disease. Movement Disorders. 17(6). 1180–1187.
17.
Fox, Susan H., Michael P. Hill, A.R. Crossman, & Jonathan M. Brotchie. (1999). On the role of endocannabinoids in L-DOPA-induced dyskinesia. The Society for Neuroscience Abstracts. 25. 1462.
18.
Hill, Michael P. & Jonathan M. Brotchie. (1999). The adrenergic receptor agonist, clonidine, potentiates the anti‐parkinsonian action of the selective κ‐opioid receptor agonist, enadoline, in the monoamine‐depleted rat. British Journal of Pharmacology. 128(7). 1577–1585.
19.
Nash, Joanne E., Michael P. Hill, & Jonathan M. Brotchie. (1999). Antiparkinsonian Actions of Blockade of NR2B-Containing NMDA Receptors in the Reserpine-Treated Rat. Experimental Neurology. 155(1). 42–48.
20.
McKnight, Alexander T., et al.. (1998). Kappa‐opioid receptor agonists increase locomotor activity in the monoamine‐depleted rat model of parkinsonism. Movement Disorders. 13(2). 228–233.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Anders Borgkvist Breakdown of academic impact, for papers by Junchao Tong Breakdown of academic impact, for papers by Annalisa Pinna Breakdown of academic impact, for papers by Krystyna Ossowska Breakdown of academic impact, for papers by Jadwiga Wardas Breakdown of academic impact, for papers by Christophe Melon Breakdown of academic impact, for papers by O. Curet Breakdown of academic impact, for papers by Joakim Tedroff Breakdown of academic impact, for papers by Patricia Tagliaferro Breakdown of academic impact, for papers by Maria Rosaria Domenici